Tg Therapeutics (TGTX) Income from Continuing Operations (2011 - 2026)
Tg Therapeutics (TGTX) recorded quarterly Income from Continuing Operations of 19777000.0 in Q1 2026, down 15.43% quarter-over-quarter from 23386000.0 in Q4 2025, and up 290.23% on a YoY basis from 5068000.0 in Q1 2025.
Tg Therapeutics (TGTX) Income from Continuing Operations (2011 - 2026) Analysis & Trends
Tg Therapeutics' Income from Continuing Operations history runs 16 years deep, the most recent figure standing at 19777000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 290.23% year-over-year to 19777000.0; the TTM figure through Mar 2026 stood at 462278000.0 (up 1055.52% YoY), while the FY2025 annual figure was 447528000.0, up 1744.79% from the prior year.
- Income from Continuing Operations was 19777000.0 for Q1 2026 at Tg Therapeutics, down from 23386000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 390895000.0 in Q3 2025 to a low of 80401000.0 in Q4 2022.
- Historically, Income from Continuing Operations has averaged 15421176.47 across 5 years, with a median of 3880000.0 in 2024.
- The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations sank 96.59% in 2024, then soared 9974.61% in 2025.
- A 5-year view of Income from Continuing Operations shows it stood at 80401000.0 in 2022, then surged by 65.18% to 27999000.0 in 2023, then jumped by 186.46% to 24207000.0 in 2024, then retreated by 3.39% to 23386000.0 in 2025, then retreated by 15.43% to 19777000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 19777000.0 (Q1 2026), 23386000.0 (Q4 2025), and 390895000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Tg Therapeutics | 7.71 Bn | 7.06 Bn | 171.41 Mn | 19.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 19.78 Mn |
| Dec 31, 2025 | 23.39 Mn |
| Sep 30, 2025 | 390.90 Mn |
| Jun 30, 2025 | 28.22 Mn |
| Mar 31, 2025 | 5.07 Mn |
| Dec 31, 2024 | 24.21 Mn |
| Sep 30, 2024 | 3.88 Mn |
| Jun 30, 2024 | 6.85 Mn |
| Mar 31, 2024 | -10.71 Mn |
| Dec 31, 2023 | -28.00 Mn |
| Sep 30, 2023 | 113.93 Mn |
| Jun 30, 2023 | -47.61 Mn |
| Mar 31, 2023 | -39.23 Mn |
| Dec 31, 2022 | -80.40 Mn |
| Sep 30, 2022 | -36.61 Mn |
| Jun 30, 2022 | -41.96 Mn |
| Mar 31, 2022 | -69.54 Mn |
| Dec 31, 2021 | -94.03 Mn |
| Sep 30, 2021 | -86.17 Mn |
| Jun 30, 2021 | -79.12 Mn |